CNBC Utilities Page Drugs

  • Report: 15 Russian Olympic champs in doping program

    A New York Times report saying at least 15 Russian gold medal winners from the last winter Olympics in Russia were part of a state-run doping program.

  • Is Uber the new side hustle?

    Technology changes things we wouldn't expect, explains Vanity Fair special correspondent Nick Bilton, after he rode in an Uber where the driver told him about transporting a drug dealer.

  • Genetic Test analytical testing in laboratory

    A new gene test claims it can slow the US painkiller addiction epidemic by identifying likely addicts before a doctor writes a prescription.

  • Can genetic testing help end America's painkiller addiction?

    Opioid addiction has led some doctors to gene tests: but can patients likely to get hooked on painkillers be guessed? CNBC's Dina Gusovsky reports.

  • Treasury on Thursday blacklisted an extensive Panama- based money laundering operation that allegedly helped multiple drug trafficking groups hide the source of their illicit gains through various companies, including Balboa Bank& Trust. The U.S. Treasury's Office of Foreign Assets Control said the operation, led by Nidal Waked Hatum and Abdul Waked Fares,...

  • NEW YORK/ WASHINGTON, May 5- The U.S. government on Thursday took wide-ranging steps to crack down for the first time on e-cigarettes and cigars, growing in popularity among teens, and banned sales to anyone under age 18 in hopes of sparing a new generation from nicotine addiction. The Food and Drug Administration's action brought regulation of e-cigarettes,...

  • NEW YORK, May 5- The former head of Venezuela's National Assembly filed a lawsuit on Thursday accusing the Wall Street Journal of libeling him in an article in which it was reported that he was the target of a U.S. drug trafficking probe. Cabello's reputation and good name, both personally and in his capacity as a key member of Venezuela's National Assembly.

  • NEW YORK, May 5- Diosdado Cabello, the former head of Venezuela's national assembly, filed a lawsuit on Thursday accusing the Wall Street Journal of libeling him in an article reporting he was the target of a U.S. drug trafficking probe. Cabello's reputation and good name, both personally and in his capacity as a key member of Venezuela's National Assembly, "the...

  • Shkreli back in court

    CNBC's Meg Tirrell reports prosecutors may file new charges against Martin Shkreli. His next court hearing is set for June 6th.

  • Next Shkreli court appearance June 6

    CNBC's Meg Tirrell reports the government is considering adding more charges against Martin Shkreli, former CEO of Turing Pharmaceuticals, at the U.S. District Court in Brooklyn Tuesday.

  • Oxycodone is a narcotic pain reliever.

    Americans want elected officials to do more to fight the growing opioid epidemic, a new survey finds.

  • Battle over Valeant

    The Fast Money traders discuss Valeant Pharmaceuticals' drug pricing strategy and the comments made by Bill Ackman and Charlie Munger.

  • GlaxoSmithKline CEO: Drug pricing in the US needs to change, here's how

    Andrew Witty, GlaxoSmithKline CEO, discusses drug pricing in the United States, innovations in health care, & more.

  • The headquarters of Valeant Pharmaceuticals International in Laval, Quebec.

    Discussing drug pricing, and drug access of Valeant Pharmaceutical products, with Bill Ackman, Pershing Square Capital CEO and portfolio manager.

  • Ackman: Coke has targeted kids in its marketing

    Bill Ackman, Pershing Square Capital CEO and portfolio manager, discusses Coca-Cola's marketing, the obesity health crisis and where he disagrees with Charlie Munger on Valeant Pharmaceuticals.

  • Bill Ackman on hedge funds

    Bill Ackman, Pershing Square Capital CEO and portfolio manager, weighs in on the troubles facing hedge funds lately.

  • Ackman: VRX undervalued, phone ringing for potential asset buyers

    Bill Ackman, Pershing Square Capital CEO and portfolio manager, weighs in on when to invest in Valeant Pharmaceuticals.

  • Bill Ackman on sticking with Valeant

    Bill Ackman, Pershing Square Capital CEO and portfolio manager, discusses his firm's influence on Valeant's changes.

  • Valeant is not 'a sewer': Bill Ackman

    Bill Ackman, Pershing Square Capital CEO and portfolio manager, discusses the changes happening at Valeant Pharmaceuticals, and his decision to invest in the company's business model, after Berkshire Hathaway Vice Chairman Charlie Munger commented the company has become a "sewer."

  • Pharmacy

    CNBC's Meg Tirrell speaks with Jim Greenwood, Biotechnology Industry Organization President and CEO, and CNBC Contributor and Former Pennsylvania Governor Ed Rendell, about the battle over drug pricing and whether more government regulation is warranted.